Squarepoint
NVO

Squarepoint’s Novo Nordisk NVO Stock Holding History

Squarepoint’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.2M Buy
468,500
+132,900
+40% +$6.3M 0.02% 788
2025
Q4 		$17.1M Sell
335,600
-304,500
-48% -$15.6M 0.02% 815
2025
Q3 		$35.5M Buy
640,100
+312,800
+96% +$18.3M 0.04% 521
2025
Q2 		$22.6M Sell
327,300
-129,600
-28% -$8.82M 0.02% 710
2025
Q1 		$31.7M Buy
456,900
+158,500
+53% +$13.1M 0.04% 487
2024
Q4 		$25.7M Buy
298,400
+260,400
+685% +$28.2M 0.03% 646
2024
Q3 		$4.52M Buy
38,000
+18,700
+97% +$2.49M 0.01% 1480
2024
Q2 		$2.75M Sell
19,300
-62,000
-76% -$8.22M ﹤0.01% 1807
2024
Q1 		$10.4M Sell
81,300
-1,800
-2% -$214K 0.02% 973
2023
Q4 		$8.6M Buy
+83,100
New +$8.22M 0.02% 1037
2023
Q1 		– Sell
-24,000
Closed -$1.62M – 3615
2022
Q4 		$1.62M Hold
24,000
– – 0.01% 1482
2022
Q3 		$1.2M Buy
+24,000
New +$1.29M 0.01% 1641

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Squarepoint's NVO Position: Q1 2026 in Review

Squarepoint reduced its Novo Nordisk (NVO) stake by 86% in Q1 2026, selling an estimated $38M and leaving 131,865 shares worth $4.85M. The position accounts for 0.01% of the portfolio, ranked #1530.

Squarepoint first reported a position in NVO in Q2 2019 and has held it in 26 quarters since. The position peaked at $60.4M in Q3 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Squarepoint held 131,865 shares of Novo Nordisk worth $4.85M as of Q1 2026.
  • Squarepoint sold 802,779 Novo Nordisk shares in Q1 2026, an estimated $38M.
  • Novo Nordisk made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1530 holding.
  • Squarepoint first reported a position in Novo Nordisk in Q2 2019 and has held it in 26 quarters since.
  • Squarepoint's Novo Nordisk position peaked at $60.4M in Q3 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.